Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIIb Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Vaccine [GSK 134612] When Given as One Dose to Healthy Subjects Aged 56 Years or Older

NCT01235975 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01235975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01235975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIIb Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Vaccine [GSK 134612] When Given as One Dose to Healthy Subjects Aged 56 Years or Older
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2010
Completion date
August 3, 2011
Enrollment
400 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infections, meningococcal